ong-term follow-up of participants from studies evaluating the HIV vaccine
- Conditions
- ART-treated and ART-naïve HIV-infected adults (ART: anti-retroviral therapy)MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2009-018097-64-DE
- Lead Sponsor
- GlaxoSmithKline Biologicals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 229
Inclusion Criteria
All subjects must satisfy ALL the following criteria at study entry:
• HIV-infected subject
• Previous participation in a study evaluating F4co/AS01B vaccine
• Written informed consent obtained from the subject
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 229
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
• Subjects who did not receive a complete vaccination course in the previous study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method